Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Taiho Takes Small-Molecule Expertise into ADCs; 3-Payload IND Due This Year
Taiho Pharmaceutical is looking to bring its small-molecule drug discovery expertise to antibody drug conjugates (ADCs), aiming to develop novel payloads that can be paired with the technology it acquired through last year’s takeover of Swiss biotech Araris Biotech. The…
To read the full story
Related Article
- Taiho Moves Araris’ ADC into PI for Lymphoma in US
April 30, 2026
- JFCR, NEC, Taiho Launch AI-Driven R&D for Cancer Vaccines
December 1, 2025
- Otsuka/Taiho Look to Leverage Araris’ Linker Tech to Create 1st-in-Class ADCs
March 21, 2025
- Taiho Picks Up Araris, Bagging 3 Key Preclinical ADCs
March 18, 2025
BUSINESS
- Taiho Takes Small-Molecule Expertise into ADCs; 3-Payload IND Due This Year
September 14, 2026
- Otsuka Steps Up Neuroplastogen Push in Psychiatry
September 14, 2026
- Medipal, JCR Launch Global PI/II of MPS IIIB Therapy
September 14, 2026
- Former Takeda CEO Yasuchika Hasegawa Dies at 80
September 11, 2026
- Takeda R&D Chief Plump to Retire in June 2027
September 11, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…